Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Updated on 13 June 2021


This is a non-randomized, phase II, open label study of Surufatinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.

Condition Head and Neck Cancers - Salivary Gland
Treatment Surufatinib
Clinical Study IdentifierNCT04910854
SponsorShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Last Modified on13 June 2021


Yes No Not Sure

Inclusion Criteria

Provision of written Informed Consent Form (ICF) prior to any study specific procedures
Male and Female aged between 18 and 75 years are eligible
Histologically or cytologically confirmed that recurrent or metastatic adenocarcinomas of the head and neck
Patients with recurrent or metastatic head and neck adenocarcinoma who are not candidates for curative surgery or refusing surgical treatment
Presence of at least one measurable target lesion for further evaluation according to RECIST criteria
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Predicted survival 6 months
Screening laboratory values must meet the following criteria (within past 14 days)
neutrophils 1.5109/L
platelets 9g/dL
hemoglobin 9.0 g/dL
total bilirubin 1.5 x upper limit of normal (ULN) aspartic transaminase (AST) and alanine transaminase (ALT) 2.5 x ULN without, and 5 x ULN with hepatic metastasis serum creatinine 1.5ULN
Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 6 months after the last dose of study drug

Exclusion Criteria

\. Prior treatment with Surufatinib,or other antiangiogenic drugs were used within 6 months; 2. Prior antitumor therapy with chemotherapy, radical radiation therapy biological immunotherapytargeted therapy within 4 weeks. 3. Prior participation in other clinical trials not approved or listed in China within past 4 weeks 4. Prior major surgery within past 4 weeks (diagnostic surgery excluded); 5. International standardized ratio (INR) >1.5 or partially activated prothrombin time (APTT) >1.5ULN; 6. Clinically significant severe electrolyte abnormality judged by investigator ; 7. Hypertension that is not controlled by the drug, and is defined as: SBP140 mmHg and/or DBP90 mmHg; 8. Currently suffering from poorly controlled diabetes (after regular treatment, fasting plasma glucose concentration 10mmol/L); 9. The patient currently has disease or condition that affects the absorption of the drug, or the patient cannot be administered orally; 10. Digestive tract disease such as gastric and duodenal active ulcer, ulcerative colitis or unresected tumor, or other conditions determined by the investigator that may cause gastrointestinal bleeding and perforation; 11. Evidence of bleeding tendency or history within 3 months, or thromboembolic event (including a stroke event and/or a transient ischemic attack) occurred within 12 month; 12. Cardiovascular disease of significant clinical significance (myocardial infarction, unstable arrhythmia or unstable angina Coronary Artery Bypass Grafting within past 6 months,) 13. Had other malignant tumors in the past 5 years (except for basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ that have been effectively controlled); 14. Active or uncontrolled severe infection (CTCAE2 infection); 15. Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>2000IU/ml); 16. Evidence with active CNS disease or previous brain metastases; 17. The toxicity associated with previous anti-tumor treatment has not recovered to CTCAE1, except for peripheral neurotoxicity and alopecia CTCAE2 caused by oxaliplatin; 18. Pregnant or nursing 19. Transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony stimulating factor (G-CSF), had been received within 14 days before enrollment; 20. Tumor involving skin and/or pharyngeal mucosa with ulceration; 21. Patients with a history of psychotropic drug abuse and unable to quit or with mental disorders; 22. Any other disease, with clinical significance of metabolic abnormalities, abnormal physical examination or laboratory abnormalities, according to researchers, there is reason to doubt is not suitable for the use of study drugs in patients with a disease or condition (such as have a seizure and require treatment), or will affect the interpretation of results, or make the patients at high risk. 23. Routine urine indicated that urine protein 2+, and the 24-hour urine protein volume >1.0g; 24. Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note